BlogRead the Latest News

 

About Burzynski: PART I

The first in the series, "Burzynski, the Movie," is an internationally award-winning documentary originally released in 2010 (with an Extended Edition released in 2011) that tells the true story of a medical doctor and Ph.D biochemist named Dr. Stanislaw Burzynski who won the largest, and possibly the most convoluted and intriguing legal battle against the Food & Drug Administration in American history.

His victorious battles with the United States government were centered around Dr. Burzynski's gene-targeted cancer medicines he discovered in the 1970's called Antineoplastons, which have currently completed Phase II FDA-supervised clinical trials in 2009 and has been given permission by the FDA to begin the final phase of FDA testing–randomized controlled clinical trials. .

When Antineoplastons are approved, it will mark the first time in history a single scientist, not a pharmaceutical company, will hold the exclusive patent and distribution rights on a paradigm-shifting medical breakthrough.

Read the complete synopsis

About Burzynski: PART II

In the compelling follow-up to the first internationally award-winning documentary, “Burzynski: Cancer is Serious Business, Part II” explores the current status of Antineoplastons' clinical testing sanctioned by the United States Food & Drug Administration—and features a modern story of the struggling journeys of cancer patients being treated today at the Burzynski Clinic in Houston, Texas.

For most patients undergoing Burzynski's treatment, their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists, but also from friends and family who feel their loved ones are making suspect treatment decisions—even though mainstream oncology has already left many for dead.

As the story unfolds, it reveals a real-time change of hearts and minds from many of these doctors and families and with candid interviews with board-certified oncologists, surgeons and neurosurgeons.

Read the complete synopsis

Fact Check The Main Documentary | Sourced Transcript

 

From Our Blog

 

Jessica Ressel-Doeden – Inoperable Diffuse Intrinsic Brainstem Glioma (DIPG) – Cured with Medical Records

Sunday, 09 August 2015 23:53
Written by

Jessica Ressel-Doeden was diagnosed with a diffuse, intrinsic, childhood brainstem glioma (DIPG) in March of 1996 at age eleven.

According to the available data there has not been a single case of a verified cure (5-year survival) with patients diagnosed with diffuse (inoperable) childhood brainstem glioma treated with radiation and/or chemotherapy in any FDA-supervised experimental clinical trial in the history of medicine. Dr. Burzynski’s Antineoplastons hold the only cures to date—with a cure rate in some studies as high as 27.5% [PDF of original report, table page 172] + [Chemo/Rad – PubMed 2005] [ANP – PubMed 2003] [ANP – PubMed 2006] [ANP – Cancer Therapy 2007]

[The Lancet 2006 explains grim outlook – “survival remains static”].

** April 2014 Peer-reviewed clinical trial report for DIPG using Antineoplastons **

Following her initial diagnosis, the Ressel’s were informed that the only method approved by the FDA to “treat” her condition would be radiation. The radiologist informed the family that radiation would be shot “through the ears, burning her healthy cells from the outside in—causing permanent deafness, all of the hair around her ears would be gone—never grow back, her ears would become deformed and burnt, her pituitary gland would be destroyed—the gland that allows a human to grow and develop, and if she survived the treatment she would become a vegetable and incapable of taking care of herself.”

Considering that radiation treatment has never been shown to cure a single patient with her condition, combined with the devastating side effects such a treatment would inflict on an eleven-year old child—her parents declined the radiation treatment offered by her oncologists and decided to have Jessica treated by Dr. Burzynski instead.

Medical Records

1. Diagnosis: Jessica underwent an MRI on April 10, 1996 at the St. Louis Children’s Hospital which revealed a tumor in her brainstem. Her diagnosis was also confirmed on May 7, 1996 upon initial consultation with Dr. Burzynski. She had multiple MRIs after she was admitted into the Burzynski Clinic. There is also multiple third-party confirmations of diagnosis by physicians from the Springfield Clinic and the Missouri Eye Institute demonstrated by letters written to the Ressel’s insurance company.

2. Recovery: On May 8, 1996, Jessica began antineoplaston treatment. Her tumor disappeared and reappeared multiple times throughout the course of 14 months after the start date of treatment. On June 27, 1997, her tumor disappeared permanently. She has had multiple MRIs of the brain since that time which have all been negative for tumor recurrence—with the last MRI being May 20, 2005. Read Jessica’s treatment summary here. Read Jessica’s tumor measurements here. After her full recovery, the Mid-Atlantic Open MRI of Springfield, MO confirmed her tumor-free MRIs from 11/97 to 5/98 [PDF all medical records and sources for this paragraph].

3. FDA-supervised clinical trial data comparing chemotherapy and radiation treatment to antineoplaston treatment in patients with diffuse, intrinsic, childhood brainstem glioma. It has been clearly demonstrated that of 107 patients treated with chemotherapy and radiation with this type of tumor: 0.9% of these patients were cancer-free at the end of treatment, with no patient surviving 5 years after diagnosis. Of the patients treated with antineoplastons with this type of tumor: 27.5% of them were cancer-free at the end of treatment, with 27.5% of the patients living at least 5 years after diagnosis. Therefore, Jessica Ressel’s recovery after being treated with antineoplastons is not a mere anecdotal case (See sources from start of this post above).

Most would assume that such results would be front page news across the world, or would be grounds for Dr. Burzynski to receive the Nobel Prize in medicine. Sadly, these peer-reviewed results have been universally ignored by mainstream medicine.

Raising the Money to Receive Her Antineoplaston Treatment

Unfortunately, most insurance companies will not cover antineoplaston treatment. The Ressel family had to come up with $6000 per month to pay for her treatment all by themselves. The high cost of antineoplaston treatment is directly due to the United States government’s refusal to allow any tax-payer money to be granted to fund the FDA-supervised clinical trials that Jessica participated in—while simultaneously granting PhRMA tens of millions of dollars to fund similar FDA-supervised clinical trials with inferior outcomes.

Below is a TV news footage montage from 1996-1997 covering Jessica’s story, fundraisers and more:

The Ronald McDonald House Charities®

During our interview with the Ressel family, Robin said that she “had called the Ronald McDonald House to see if we’d be able to stay there, because we were going to have to stay in Houston for a while, I was talking to a volunteer on the phone—when I mentioned we had an eleven-year old we were taking to see Dr. Burzynski and we needed a place to stay for a couple of weeks—you could hear whispering going on in the background, the volunteer was being prompted what to say, and The Ronald McDonald House refused to allow us to stay there because we weren’t an M.D. Anderson patient. I felt bad for the volunteer, you could tell she was being told what to say.” Dan followed up by saying “There are a lot of programs out there, but I will never give a dime to the Ronald McDonald House. We were in a desperate situation, and they refused us because we were a patient of Dr. Burzynski”.

Joining the Fight in Preserving Burzynski’s Freedom

Jessica Ressel was being treated by Dr. Burzynski in 1996, several months after the FDA’s 5th grand jury against Dr. Burzynski resulted in an indictment. “The government was more frustrating than the cancer itself.” The Ressel family traveled to Washington DC to meet hundreds of other Burzynski patients to speak out against the FDA’s attempt to remove him from society.

Family Speaks Out

Jessica Ressel’s medical records are published by written authorization by Jessica Ressel-Doeden.


2015: Texas Medical Board vs. Burzynski (again)

Sunday, 09 August 2015 23:05
Written by

The attempts to knock Burzynski out of business is like a game of “whack-a-mole” between state and federal agencies. For the time being the FDA is leaving Burzynski alone, but the Texas Medical Board (TMB) is trying to shut his clinic down once again.

The Texas Medical Board can no longer go after Burzynski for using Antineoplastons, as they lost countless court cases against Burzynski, ending in the State Supreme Court. Now they have changed their tactics and going after him in other ways. This case, like the countless ones before it will be a loss for the TMB, but the TMBG isn’t interested in winning any of the cases, it is a way to attempt to drain Burzynski financially.

Read the latest “complaint” against Burzynski here. Their lead prosecutor left the case for unknown reasons, postponing the case until November of this year. This is an interesting read from an independent moderator at “Dr. Social”, here.

Lt. Col. James Treadwell – Glioblastoma Multiforme Grade IV – Cured with Medical Records – brain cancer

Sunday, 09 August 2015 23:01
Written by


James Treadwell was diagnosed with a Glioblastoma Multiforme Grade IV brain tumor in 2004. He has been cancer-free since 2006. An MRI performed in 2010 has confirmed that he is still cancer-free today.

#1 Diagnosis: Pathologists performed a biopsy at the Naval Medical Center in San Diego, CA establishing his diagnosis [PDF]. A second opinion was sought at the UCLA Medical Center which also verified his diagnosis [PDF]. See the Baseline MRI: 9/22/2004 [view image].

#2 Prior Treatment: Prior to Antineoplaston treatment, James Treadwell underwent two surgeries (craniotomies), a Gliadel wafter placement, six weeks of standard radiation treatment (from June 22 to August 4, 2004), three cycles of Temodar® chemotherapy (from June 23 to August 20, 2004). None of these treatments cured Mr. Treadwell of his cancer. In fact, after the second surgery no residual cancer was found, and after the course of radiation and chemotherapy his cancer had returned and doubled in size by September 14, 2004.

#3 Recovery: After two surgeries, a Gliadel wafer, and 6 weeks of both chemotherapy and radiation failed to rid Mr. Treadwell of his brain cancer—on September 24, 2004 James Treadwell was admitted for administration of Antineoplaston treatment. He did not receive any other treatment other than Antineoplaston treatment after September 24, 2004. On November 30, 2006 his cancer was gone [PDF of tumor measurements]. [PDF of ANP treatment summary]; [11/30/2006 MRI image]; [11/2008 MRI image].

#4 Treating Glioblastoma Multiforme Grade IV without Antineoplastons. In 2010, some German scientists have admitted total defeat: “For patients with relapsed GBM [Glioblastoma Multiforme] there is currently no standard systemic therapy.”

The New England Journal of Medicine Published a study from 2005 stated: “Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide [Temodar®], given concomitantly with and after radiotherapy, in terms of efficacy and safety.” This is the same treatment Mr. Treadwell received prior to being treated with Antineoplastons.

It should be noted that Senator Ted Kennedy died of Glioblastoma Grade IV brain cancer. Countless Glioblastoma survivors cured by Antineoplastons as well as many other people cured of other types of cancer due to Antineoplastons flooded Kennedy’s office to share with him the existence of Antineoplastons. Mr. Kennedy’s wife wrote the Burzynski’s Clinic requesting all communication from Antineoplaston treated cancer survivors stop contacting his office entirely. A year later, Kennedy was dead. Lt. Col. James Treadwell’s medical records are published by written authorization by Lt. Col. James Treadwell.

Sophia Gettino – Pinealoblastoma – Cured with Medical Records

Saturday, 08 August 2015 00:21
Written by

Sophia Gettino Pinealoblastoma Cured


Sophia Gettino was diagnosed with a pinealoblastoma brain tumor on December 18, 1996—when she was 10 months old. [1]

Sophia was born in January 1996. In December of 1996, Sophia’s parents noticed that she was having trouble with her motor skills, displaying a decrease in appetite, and had noticeable swelling of the head.

After several visits to the pediatrician’s office, they decided to have an MRI conducted to see if anything was wrong with her brain. The MRI revealed a mass measuring nearly 3 cm in her brain. On December 18, 1996 a biopsy was performed by the pathology department at the Syracuse Health Center in Syracuse, New York—which diagnosed Sophia with a deadly pinealoblastoma brain tumor.

On December 20, 1996 surgeons at the Syracuse Health Center removed nearly all of her tumor, but were unable to remove it all without injuring Sophia any further.

In their evaluation report oncologists at Syracuse stated “Because of her age, short onset of symptoms and pathologic findings, her prognosis unfortunately is very poor. The option of chemotherapy was presented to the family.”

The chemotherapy offered to Sophia was a combination of thiotepa, etoposide, and carboplatine.

Thiotepa Chemotherapy was approved by the FDA on March 9, 1959. This drug was approved for breast, ovary, and bladder cancer primarily. To date, thiotepa’s “safety and effectiveness in pediatric patients have not been established.” The expected side effects of this chemotherapy in non-pediatric patients are: low blood cell count, vomiting, infertility, hair loss, blurred vision, and being a carcinogen causes more cancer.

Etoposide Chemotherapy was approved by the FDA on November 11, 1983. This drug is used to treat people with testicular cancer or small cell lung cancer. In pediatric patients, etoposide’s “safety and efficacy have not been established”. The side effects in non-pediatric patients receiving this therapy include leukemia, nerve damage, inability to fight infections, and vomiting. There is limited evidence to verify whether or not this drug used alone causes more cancer, but there is sufficient evidence that when used with other chemotherapy that is does cause cancer.

Carboplatine Chemotherapy was approved in the late 1980’s and is primarily used to treat ovarian, lung, and head and neck cancers. “the most troubling effects of carboplatin tends to be damage to the bone marrow…” Other side effects include damage to the nervous system, mouth sores, loss of appetite, stomach pain, diarrhea, vomiting, and changes in vision.

After understanding that these chemotherapeutic drugs would not likely save Sophia, combined with the side effects this chemotherapy regimen could cause to their daughter, Sophia’s parents declined all chemotherapy treatment offered by their oncologists and decided to explore other methods of treatment. Upon this search for another option they found the Burzynski Clinic.

On February 27, 1997 Sophia was admitted for antineoplaston therapy in a FDA-supervised Phase II clinical trial. She discontinued antineoplaston therapy on March 7, 2003 due to a complete response. She is alive, healthy, and remains cancer-free today. (A residual, benign tumor is still left in her brain, but all signs of malignancy have disappeared and have not returned to date).

Medical Records

Diagnosis:
1. December 18, 1996 pathology report from Syracuse Health Center.
2. December 25, 1996 Syracuse Health oncology evaluation report verifying diagnosis, with suggested experimental chemotherapy regimen.
Baseline MRI of the brain on February 26, 1997 showing a massive tumor in her brain.

Recovery:
4. Sophia’s Phase II FDA-clinical trial treatment summary
5. Tumor Measurements from start of treatment to declaration of “complete response”.
6. A third party confirmation of complete response from J.C. Pleasure, MD of Oncoimaging, P.A. in Herdon, VA
7. February 3, 2003 MRI scan showing the residual benign remnants of the once malignant tumor.

Comparing the FDA clinical trial data for this type of tumor

In a group of Phase II clinical trials using only Antineoplastons, with 13 children ranging from one to eleven years old with PNET tumors: Six of those patients (46%) survived more than 5 years after treatment. Five of the six patients had not undergone any previous chemotherapy or radiation prior to being treated with Antineoplastons. Click here to read this study’s abstract.

In contrast, a chemotherapy drug produced by GlaxoSmithKline called Topotecan (also a gene-targeted drug), is undergoing Phase II trials for this type of tumor in children as well. Twenty-six children were treated, two objective responses were noted (7.6%), and these two patients managed to live beyond five years. However, this does not indicate the damage, if any, this chemotherapeutic drug caused these patients. Click here to read this study.

Therefore, in virtually identical Phase II gene-targeted clinical trials treating PNET in children: topotecan chemotherapy resulted in a 7.6% 5-year survival; while Antineoplastons resulted a 46% 5-year survival. It’s important to note that while Antineoplastons are free of harmful side effects, topotecan’s side effects generally include: hair loss, vomiting, and diarrhea—if you are lucky. If you are one that has a more severe reaction to this drug, the side effects can include: difficulty breathing; swelling of the face, lips and tongue; severe cough; painful urination, unexplained bruising, and stomach cramps. Click here more on this drug.

Sophia Gettino’s medical records are published by written authorization by her family.

OWN IT.
Get both DVDs for $19.99